Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Multiple Myeloma News

Conference Coverage
Updated, Longer-term Efficacy Data Following Subsequent Therapy in ICARIA-MM
12/10/2022

Craig Ostroff

Craig Ostroff
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Paul G Richardson, MD, and...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
A 12-Gene Signature Accurately Predicts Progression From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
12/10/2022

Craig Ostroff

Craig Ostroff
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Speaking at the 64th ASH Annual...
12/10/2022
Journal of Clinical Pathways

Advertisement

News
Belantamab in Combination With Dexamethasone Demonstrates Good Clinical Activity in Triple-Class Relapsed/Refractory MM
09/12/2022

Yvette C Terrie

Yvette C Terrie
Outcomes in relapsed/refractory myeloma remain poor, and novel therapy approaches are necessary, according to findings from a study published in Clinical Lymphoma, Myeloma & Leukemia.
Outcomes in relapsed/refractory myeloma remain poor, and novel therapy approaches are necessary, according to findings from a study published in Clinical Lymphoma, Myeloma & Leukemia.
Outcomes in relapsed/refractory...
09/12/2022
Journal of Clinical Pathways
News
Clinical Significance of CTCs in Staging of Newly Diagnosed Transplant-Eligible Patients With Multiple Myeloma
08/16/2022

Yvette C Terrie

Yvette C Terrie
The assessment of circulating tumor cells in peripheral blood outperformed quantification of bone marrow plasma cells and the discovery of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible...
The assessment of circulating tumor cells in peripheral blood outperformed quantification of bone marrow plasma cells and the discovery of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible...
The assessment of circulating...
08/16/2022
Journal of Clinical Pathways
News
Exploring Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed MM
08/11/2022

Yvette C Terrie

Yvette C Terrie
Patients with newly diagnosed multiple myeloma treated with combination regimen of bortezomib, lenalidomide, and dexamethasone induction followed by early autologous stem cell transplantation (ASCT) may not have a greater occurrence of...
Patients with newly diagnosed multiple myeloma treated with combination regimen of bortezomib, lenalidomide, and dexamethasone induction followed by early autologous stem cell transplantation (ASCT) may not have a greater occurrence of...
Patients with newly diagnosed...
08/11/2022
Journal of Clinical Pathways

Advertisement

News
Systematic Review Protocol Explores Impact of Bortezomib in Multiple Myeloma Treatment
07/27/2022

Ellen Kurek

Ellen Kurek
Researchers detailed their systematic review protocol which will aim to evaluate the effects of bortezomib on the overall survival, progression-free survival, overall response rate, time to next treatment, health-related quality of life,...
Researchers detailed their systematic review protocol which will aim to evaluate the effects of bortezomib on the overall survival, progression-free survival, overall response rate, time to next treatment, health-related quality of life,...
Researchers detailed their...
07/27/2022
Journal of Clinical Pathways
News
Comparative Effectiveness of Ciltacabtagene Autoleucel vs Physician’s Choice of Therapy for Relapsed or Refractory Multiple Myeloma
05/16/2022

Ellen Kurek

Ellen Kurek
Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.
Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.
Ciltacabtagene autoleucel...
05/16/2022
Journal of Clinical Pathways
News
Cost and Utilization of Daratumumab in Patients With Multiple Myeloma
05/02/2022

Ellen Kurek

Ellen Kurek
In patients with multiple myeloma, daratumumab is utilized more frequently than the FDA-recommended dosing, which may lead to higher treatment costs.
In patients with multiple myeloma, daratumumab is utilized more frequently than the FDA-recommended dosing, which may lead to higher treatment costs.
In patients with multiple...
05/02/2022
Journal of Clinical Pathways

Advertisement

News
Patients With Multiple Myeloma Incur High Health Care Costs During Follow-up
04/25/2022

Ellen Kurek

Ellen Kurek
A recent health care claims databases analysis revealed that among patients with MM, the mean, total, all-cause health care cost during 21 months of follow-up was found to be nearly $723,000.
A recent health care claims databases analysis revealed that among patients with MM, the mean, total, all-cause health care cost during 21 months of follow-up was found to be nearly $723,000.
A recent health care claims...
04/25/2022
Journal of Clinical Pathways
News
Isatuximab Added to Pomalidomide and Dexamethasone Extends OS in Relapsed and Refractory MM
03/01/2022

Janelle Bradley

Janelle Bradley
Study findings show the addition of isatuximab to pomalidomide and dexamethasone extended OS compared to pomalidomide and dexamethasone in lenalidomide-refractory and proteasome inhibitor-refractory or relapsed MM.
Study findings show the addition of isatuximab to pomalidomide and dexamethasone extended OS compared to pomalidomide and dexamethasone in lenalidomide-refractory and proteasome inhibitor-refractory or relapsed MM.
Study findings show the addition...
03/01/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use